SCYNEXIS Inc Corporate Commercial Launch Update Corporate Call Transcript
Good afternoon, and welcome to the SCYNEXIS Conference Call. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the SCYNEXIS' website following the conclusion of the event. I would now like to turn the call over to Irina Koffler of LifeSci Advisors. You may being.
Good afternoon, and thank you for joining us as we provide a corporate update on the pending BREXAFEMME launch for the treatment of VVC. Joining me today from SCYNEXIS are Dr. Marco Taglietti, President and Chief Executive Officer; Dr. Michael Krychman, Health Science, Clinical Professor at the University of California Irvine, Division of Gynecological Oncology; Christine Coyne, Chief Commercial Officer; and Eric Francois, Chief Financial Officer.
During this call, please note, we will be making forward-looking statements. These statements are subject to factors, risks and uncertainties, including those that are detailed in today's presentation and our Form 10-K for the year ended December 31,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |